Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tocilizumab biobetter - Beijing Weidejie Biotechnology

Drug Profile

Tocilizumab biobetter - Beijing Weidejie Biotechnology

Alternative Names: IL-6R monoclonal antibody injection - Beijing Weidejie Biotechnology; Tocilizumab injection - Beijing Weidejie Biotechnology; VDJ 001

Latest Information Update: 31 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Weidejie Biotechnology
  • Class Antirheumatics; Biobetters; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Giant lymph node hyperplasia; Rheumatoid arthritis

Most Recent Events

  • 02 Jun 2023 Beijing Weidejie Biotechnology completes a phase II trial in Rheumatoid arthritis (Treatment-experienced) in China (IV) (NCT05957107)
  • 18 Apr 2022 Phase-II clinical trials in Giant lymph node hyperplasia in China (IV) (NCT05345522)
  • 14 Feb 2022 Beijing VDJBio completes a phase I/II trial in Rheumatoid arthritis (Treatment experienced) in China (IV) (NCT05232396)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top